

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors

Status: Recruiting

Eligibility Criteria

Sex: Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of high-grade serous/endometrioid ovarian, primary peritoneal, or fallopian tube or endometrial cancer that is metastatic or not able to have surgical treatment
- received or are intolerant to 1 but no more than 3 lines of prior systemic therapy - able to walk and do all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours - see link to clinicaltrials.gov for complete inclusion criteria

Exclusion Criteria:

- pleural/abdominal effusion/ascites requiring clinical intervention or presence of pericardial effusion - brain metastasis unless asymptomatic - heart arrhythmias or ECG abnormalities - Left ventricular ejection fraction (LVEF) < 50% - see link to clinicaltrials.gov for complete exclusion criteria

Conditions & Interventions

Interventions:

Drug: GSK5733584

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), cancer, neoplasm, solid tumors

More Information

Description: This study is being done to test if GSK5733584, the study drug, can improve cancer, is safe, well-tolerated, works and helps to treat cancer, how the body reacts to and how the body uses the study drug at different doses.

Study Contact: Deanna Teoh - dkteoh@umn.edu

Principal Investigator: Deanna Teoh

Phase: PHASE1

IRB Number: STUDY00025827

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.